78 related articles for article (PubMed ID: 20332439)
21. Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia.
Moon E; Lee R; Near R; Weintraub L; Wolda S; Lerner A
Clin Cancer Res; 2002 Feb; 8(2):589-95. PubMed ID: 11839681
[TBL] [Abstract][Full Text] [Related]
22. Expression and functional activity of phosphodiesterase type 5 in human and rabbit vas deferens.
Mancina R; Filippi S; Marini M; Morelli A; Vignozzi L; Salonia A; Montorsi F; Mondaini N; Vannelli GB; Donati S; Lotti F; Forti G; Maggi M
Mol Hum Reprod; 2005 Feb; 11(2):107-15. PubMed ID: 15640438
[TBL] [Abstract][Full Text] [Related]
23. The role of phosphodiesterase isoforms 2, 5, and 9 in the regulation of NO-dependent and NO-independent cGMP production in the rat cervical spinal cord.
de Vente J; Markerink-van Ittersum M; Vles JS
J Chem Neuroanat; 2006 Jun; 31(4):275-303. PubMed ID: 16621445
[TBL] [Abstract][Full Text] [Related]
24. Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue.
Uckert S; Sormes M; Kedia G; Scheller F; Knapp WH; Jonas U; Stief CG
Urology; 2008 Mar; 71(3):526-30. PubMed ID: 18342202
[TBL] [Abstract][Full Text] [Related]
25. Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells.
Growcott EJ; Spink KG; Ren X; Afzal S; Banner KH; Wharton J
Respir Res; 2006 Jan; 7(1):9. PubMed ID: 16423283
[TBL] [Abstract][Full Text] [Related]
26. Dexamethasone down-regulates cAMP-phosphodiesterase in human osteosarcoma cells.
Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
Biochem Pharmacol; 2005 Jan; 69(2):267-75. PubMed ID: 15627479
[TBL] [Abstract][Full Text] [Related]
27. New insight into the role of phosphodiesterase 3A in porcine oocyte maturation.
Sasseville M; Côté N; Guillemette C; Richard FJ
BMC Dev Biol; 2006 Oct; 6():47. PubMed ID: 17038172
[TBL] [Abstract][Full Text] [Related]
28. Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells.
Mata M; Sarriá B; Buenestado A; Cortijo J; Cerdá M; Morcillo EJ
Thorax; 2005 Feb; 60(2):144-52. PubMed ID: 15681504
[TBL] [Abstract][Full Text] [Related]
29. Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis.
Netherton SJ; Maurice DH
Mol Pharmacol; 2005 Jan; 67(1):263-72. PubMed ID: 15475573
[TBL] [Abstract][Full Text] [Related]
30. Cyclic nucleotide phosphodiesterases (PDEs) in human osteoblastic cells; the effect of PDE inhibition on cAMP accumulation.
Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
Cell Mol Biol Lett; 2005; 10(2):305-19. PubMed ID: 16010295
[TBL] [Abstract][Full Text] [Related]
31. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility.
Nagendran J; Archer SL; Soliman D; Gurtu V; Moudgil R; Haromy A; St Aubin C; Webster L; Rebeyka IM; Ross DB; Light PE; Dyck JR; Michelakis ED
Circulation; 2007 Jul; 116(3):238-48. PubMed ID: 17606845
[TBL] [Abstract][Full Text] [Related]
32. The role of the novel Th17 cytokine IL-26 in intestinal inflammation.
Dambacher J; Beigel F; Zitzmann K; De Toni EN; Göke B; Diepolder HM; Auernhammer CJ; Brand S
Gut; 2009 Sep; 58(9):1207-17. PubMed ID: 18483078
[TBL] [Abstract][Full Text] [Related]
33. In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors.
Gantner F; Kupferschmidt R; Schudt C; Wendel A; Hatzelmann A
Br J Pharmacol; 1997 May; 121(2):221-31. PubMed ID: 9154331
[TBL] [Abstract][Full Text] [Related]
34. SPARC is expressed in human uveal melanoma and its abrogation reduces tumor cell proliferation.
Maloney SC; Marshall JC; Antecka E; Orellana ME; Fernandes BF; Martins C; Castiglione E; DI Cesare S; Logan P; Burnier MN
Anticancer Res; 2009 Aug; 29(8):3059-64. PubMed ID: 19661316
[TBL] [Abstract][Full Text] [Related]
35. Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition.
Klein T; Eltze M; Grebe T; Hatzelmann A; Kömhoff M
Cardiovasc Res; 2007 Jul; 75(2):390-7. PubMed ID: 17383621
[TBL] [Abstract][Full Text] [Related]
36. Conversion of phosphodiesterase-5 (PDE5) catalytic site to higher affinity by PDE5 inhibitors.
Blount MA; Zoraghi R; Bessay EP; Beasley A; Francis SH; Corbin JD
J Pharmacol Exp Ther; 2007 Nov; 323(2):730-7. PubMed ID: 17690252
[TBL] [Abstract][Full Text] [Related]
37. Profiling of functional phosphodiesterase in mesangial cells using a CRE-SEAP-based reporting system.
Zhu Y; Yao J; Meng Y; Kasai A; Hiramatsu N; Hayakawa K; Miida T; Takeda M; Okada M; Kitamura M
Br J Pharmacol; 2006 Jul; 148(6):833-44. PubMed ID: 16751794
[TBL] [Abstract][Full Text] [Related]
38. Expression of PDE5 splice variants during ontogenesis of chick dorsal root ganglia.
Giordano D; Giorgi M; Tata AM; Modica A; Augusti-Tocco G
J Neurosci Res; 2004 Dec; 78(6):815-23. PubMed ID: 15505792
[TBL] [Abstract][Full Text] [Related]
39. Type 5 phosphodiesterase expression is a critical determinant of the endothelial cell angiogenic phenotype.
Zhu B; Zhang L; Alexeyev M; Alvarez DF; Strada SJ; Stevens T
Am J Physiol Lung Cell Mol Physiol; 2009 Feb; 296(2):L220-8. PubMed ID: 19028977
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of PDE5 and PDE9 expression in benign and malignant breast tumors.
Karami-Tehrani F; Moeinifard M; Aghaei M; Atri M
Arch Med Res; 2012 Aug; 43(6):470-5. PubMed ID: 22960860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
